ClinicalTrials.gg
Not yet recruitingNCT07841626Updated Sep 25, 2026

Safety, Pharmacokinetics, and Pharmacodynamics of Continuous KL0011034 Infusion in Healthy Chinese Adults

A Phase 1 interventional study of KL0011034 Injection and Propofol Injectable Emulsion in Healthy Participants Study and General Anesthesia, sponsored by The Third Xiangya Hospital of Central South University. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by The Third Xiangya Hospital of Central South University · Phase 1, Interventional, and Other

Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of continuous intravenous infusion of KL0011034 Injection in healthy Chinese adults. Approximately 30 participants will be enrolled in three sequential infusion-duration cohorts (1, 2, and 3 hours; 10 participants per cohort). Within each cohort, participants will be randomized in a 4:1 ratio to KL0011034 Injection or active-control propofol for anesthesia maintenance. All participants will receive propofol 2 mg/kg for anesthesia induction. Safety, pharmacokinetic, pharmacodynamic, recovery, and anesthesia-satisfaction assessments will be performed through 24 hours after dosing. Progression to the next infusion-duration cohort will occur only after the preceding cohort is considered safe and tolerable.

Read the detailed description

This is a single-center, randomized, blinded, active-controlled Phase 1 study in 30 healthy Chinese adults. The study contains three sequential cohorts defined by anesthesia-maintenance duration: 1 hour, 2 hours, and 3 hours. Each cohort will enroll approximately 10 participants. Within each cohort, participants will be randomized 4:1 to the investigational-maintenance regimen or the active-control-maintenance regimen.

All participants will receive propofol injectable emulsion 2 mg/kg intravenously over 1 minute (±5 seconds) for anesthesia induction. Maintenance infusion will begin within 30 seconds after induction. Participants assigned to the investigational regimen will receive KL0011034 Injection at a recommended maintenance rate of 1.1 mg/kg/hour; the rate may be adjusted by the investigator to maintain a bispectral index (BIS) of 40 to 60 and must not exceed the protocol-defined upper limit. Participants assigned to the active comparator will receive propofol injectable emulsion at a suggested rate of 4 to 12 mg/kg/hour, adjustable to maintain BIS at 40 to 60.

The 1-hour cohort will be evaluated before the 2-hour cohort begins, and the 2-hour cohort will be evaluated before the 3-hour cohort begins. Progression requires review confirming acceptable safety and tolerability. Participants will undergo safety monitoring, serial plasma sampling for noncompartmental pharmacokinetic analysis, and pharmacodynamic and recovery assessments including MOAA/S, BIS, Modified Aldrete Score, PADSS, recovery quality, and anesthesia satisfaction. The study includes screening, a 1-day baseline period, and approximately 24 hours of post-dose observation.

02

Conditions studied

  • Healthy Participants Study
  • General Anesthesia

Keywords

  • KL0011034
  • Continuous Intravenous Infusion
  • General Anesthesia
  • Pharmacokinetics
  • Pharmacodynamics
  • Bispectral Index
  • Healthy Participants
03

In context

Lead sponsor

The Third Xiangya Hospital of Central South University is the lead sponsor of 99 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who fully understand the purpose, content, procedures, and possible risks of the study, voluntarily agree to participate, and sign the form.
  2. Healthy male or female participants aged 18 to 45 years, inclusive, at the time of informed consent.
  3. Body weight ≥50.0 kg for males and ≥45.0 kg for females; 19.0 to 26.0 kg/m², inclusive.
  4. From informed consent through 3 months after completion of study-drug infusion, the participant and partner have no reproductive plans and the participant has no sperm or egg donation plans; the participant agrees to use at least one non-pharmacologic method through the last pharmacokinetic sample and effective contraception through 3 months after infusion.
  5. Able to communicate well with the investigator and willing and able to comply with protocol-specified lifestyle restrictions and complete study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to etomidate, propofol, or other anesthetic drugs; allergic constitution (for example, allergy to two or more drugs, foods, or pollen); tendency to rash or urticaria; history of allergic disease; or known allergy to the active ingredient or of KL0011034 Injection.
  2. History of cardiovascular, endocrine, respiratory, gastrointestinal, urinary, neurologic, hematologic, lymphatic, or psychiatric disease that remains clinically significant at screening in the investigator's judgment.
  3. History of anesthesia accident, serious anesthesia-related adverse reaction, or family history of anesthesia accident.
  4. Difficult ventilation, suspected difficult airway, or anticipated difficult tracheal intubation, including Modified Mallampati Class III-IV, congenital small mouth with macroglossia, mandibular hypoplasia, or similar findings.
  5. History of airway disease before or at screening, including bronchial asthma, , or sleep apnea syndrome.
  6. History of adrenocortical insufficiency, adrenal tumor, hereditary disorder of heme biosynthesis, or hereditary acute porphyria.
  7. Clinically significant abnormal findings in physical examination, vital signs, posteroanterior chest radiograph, abdominal ultrasonography, hematology, urinalysis, blood chemistry, coagulation, or infectious-disease screening; or clinically significant abnormal overall circadian pattern of cortisol and/or ACTH at screening in the investigator's judgment.
  8. Clinically significant abnormality at screening, including ≥450 ms in males or ≥460 ms in females.
  9. Pregnant or breastfeeding female, or a woman of with a positive pregnancy test during screening.
  10. Unprotected sexual intercourse within 2 weeks before dosing.
  11. History of drug abuse or drug dependence within 1 year before screening, or positive urine drug screen at screening.
  12. History of alcohol abuse within 6 months before screening, defined as more than 14 standard units per week (1 unit = 360 mL beer, 45 mL of 40% spirits, or 150 mL wine); positive breath alcohol test; or unwillingness to abstain from alcohol and alcohol-containing products during the study.
  13. Smoking ≥5 cigarettes per day within 6 months before screening; unwillingness to stop using tobacco products during the study; or positive smoking test at screening.
  14. Habitual consumption of more than 8 cups per day (1 cup = 250 mL) of tea, coffee, or caffeine-containing beverages, or unwillingness to abstain from these beverages during the study.
  15. Consumption of grapefruit-rich foods or beverages within 48 hours before first dosing.
  16. Use of any prescription drug, over-the-counter drug, traditional Chinese medicine, health supplement, or vitamin within 14 days before screening; or use of sedative/analgesic or other anesthetic drugs within 5 days before first dosing.
  17. Participation in any clinical trial within 3 months before dosing, or still in the follow-up period of another trial.
  18. Receipt of an inactivated vaccine within 1 month before screening or a live/attenuated vaccine within 3 months before screening, or planned vaccination during the study.
  19. Blood loss, blood donation, blood transfusion, or receipt of blood products totaling more than 400 mL within 3 months before screening; or planned blood donation or surgery during the study or within 1 month after study completion.
  20. Surgery within 3 months before screening, incomplete recovery from surgery, or planned surgery during the study.
  21. Special dietary requirements incompatible with standardized meals, swallowing difficulty, habitual anorexia or dieting, or initiation of a markedly abnormal diet (for example, a restrictive or low-sodium diet) within 4 weeks before screening.
  22. Difficult venous access, inability to tolerate venipuncture, or history of fainting in response to blood or needles.
  23. Expected poor compliance or any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort 1: KL0011034, 1-Hour Infusion

    Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by KL0011034 Injection at a recommended maintenance rate of 1.1 mg/kg/hour for 1 hour. The rate may be adjusted to maintain BIS 40-60 within protocol limits.

    Drug: KL0011034 Injection

  • Active comparator
    Cohort 1: Propofol, 1-Hour Infusion

    Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by propofol injectable emulsion at 4-12 mg/kg/hour for 1 hour. The rate may be adjusted to maintain BIS 40-60.

    Drug: Propofol Injectable Emulsion

  • Experimental
    Cohort 2: KL0011034, 2-Hour Infusion

    Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by KL0011034 Injection at a recommended maintenance rate of 1.1 mg/kg/hour for 2 hours. The rate may be adjusted to maintain BIS 40-60 within protocol limits.

    Drug: KL0011034 Injection

  • Active comparator
    Cohort 2: Propofol, 2-Hour Infusion

    Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by propofol injectable emulsion at 4-12 mg/kg/hour for 2 hours. The rate may be adjusted to maintain BIS 40-60.

    Drug: Propofol Injectable Emulsion

  • Experimental
    Cohort 3: KL0011034, 3-Hour Infusion

    Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by KL0011034 Injection at a recommended maintenance rate of 1.1 mg/kg/hour for 3 hours. The rate may be adjusted to maintain BIS 40-60 within protocol limits.

    Drug: KL0011034 Injection

  • Active comparator
    Cohort 3: Propofol, 3-Hour Infusion

    Participants receive propofol injectable emulsion 2 mg/kg IV for induction, followed by propofol injectable emulsion at 4-12 mg/kg/hour for 3 hours. The rate may be adjusted to maintain BIS 40-60.

    Drug: Propofol Injectable Emulsion

Interventions

  • Intravenous maintenance infusion at a recommended rate of 1.1 mg/kg/hour for 1, 2, or 3 hours according to assigned cohort. The investigator may adjust the rate to maintain BIS 40-60; any upward adjustment must remain within the protocol-defined maximum rate of 2.5 mg/kg/hour.

  • All participants receive 2 mg/kg intravenously over 1 minute (±5 seconds) for anesthesia induction. In active-comparator arms, maintenance propofol is infused at a suggested rate of 4-12 mg/kg/hour for 1, 2, or 3 hours according to assigned cohort, adjustable to maintain BIS 40-60.

06

What researchers measure

Primary outcomes

  1. Adverse Events and Serious Adverse Events

    Incidence, severity, seriousness, relationship, and outcome of adverse events and serious adverse events.

    Time frame: From informed consent through Day 2 discharge/early termination; unresolved adverse events are followed as specified in the protocol.

  2. Physical Examination Findings

    Number of participants with clinically significant changes or abnormalities in physical examination findings.

    Time frame: Screening, Day -2 as applicable, Day -1, Day 2/end-of-study, and early termination.

  3. Holter Monitoring Findings

    Clinically significant abnormalities detected by protocol-specified Holter monitoring.

    Time frame: Time-matched baseline on Day -1; Day 1 from infusion start through 24 hours after infusion at protocol-specified time points (infusion start; 30 minutes, 1, 2, 3 hours after start; 2, 10, 30 minutes, 1, 4, 12, 24 hours after completion).

  4. Plasma Cortisol Concentration

    Plasma cortisol concentration (measured in nmol/L) assessed by protocol-specified laboratory testing.

    Time frame: Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.

  5. Plasma Adrenocorticotropic Hormone Concentration

    Plasma adrenocorticotropic hormone (ACTH) concentration (measured in pg/mL) assessed by protocol-specified laboratory testing.

    Time frame: Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.

  6. Blood Pressure

    Change from baseline in blood pressure (systolic and diastolic, measured in mmHg) assessed by standard vital sign measurement.

    Time frame: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

  7. Pulse Rate

    Change from baseline in pulse rate (measured in beats per minute) assessed by standard vital sign measurement.

    Time frame: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

  8. Respiratory Rate

    Change from baseline in respiratory rate (measured in breaths per minute) assessed by standard vital sign measurement.

    Time frame: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

  9. Body Temperature

    Change from baseline in tympanic body temperature (measured in degrees Celsius) assessed by standard vital sign measurement.

    Time frame: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

  10. Oxygen Saturation (SpO2)

    Change from baseline in oxygen saturation (measured as percentage of oxygen saturation) assessed by pulse oximetry.

    Time frame: Day 1: pre-dose; during infusion at 30 minutes, 1, 2, 3 hours; post-infusion at 30 minutes, 1, 2, 4, 8, 12, 24 hours; and at early termination.

  11. Heart Rate

    Change from baseline in heart rate (measured in beats per minute) assessed by 12-lead electrocardiogram.

    Time frame: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

  12. PR Interval

    Change from baseline in PR interval (measured in milliseconds) assessed by 12-lead electrocardiogram.

    Time frame: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

  13. Change From Time-Matched Baseline in Plasma Cortisol Concentration

    Change from time-matched baseline in plasma cortisol concentration (measured in nmol/L) assessed by protocol-specified laboratory testing.

    Time frame: Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.

  14. QRS Interval

    Change from baseline in QRS interval (measured in milliseconds) assessed by 12-lead electrocardiogram.

    Time frame: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

  15. QT Interval

    Change from baseline in QT interval (measured in milliseconds) assessed by 12-lead electrocardiogram.

    Time frame: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

  16. QTcF Interval

    Change from baseline in QT interval corrected using Fridericia's formula (measured in milliseconds) assessed by 12-lead electrocardiogram.

    Time frame: Pre-dose (within 1 hour before anesthesia induction); after completion of continuous infusion at 30 minutes (±5 minutes), 2 hours (±10 minutes), 4 hours (±10 minutes), 8 hours (±15 minutes), and 24 hours (±20 minutes); and at early termination.

  17. Change From Time-Matched Baseline in Plasma Adrenocorticotropic Hormone Concentration

    Change from time-matched baseline in plasma adrenocorticotropic hormone (ACTH) concentration (measured in pg/mL) assessed by protocol-specified laboratory testing.

    Time frame: Screening (Day -14 to Day -2) at 07:00-08:00, 16:00 , and 00:00; time-matched baseline on Day -1; on Day 1, pre-dose, at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, and 8 hours after infusion start, and at 16:00 and 00:00; and on Day 2 at 08:00.

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of KL0011034

    Maximum observed plasma concentration.

    Time frame: pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  2. Time to Maximum Plasma Concentration (Tmax) of KL0011034

    Time of the first occurrence of the maximum observed plasma concentration.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  3. Area Under the Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of KL0011034

    Calculated using the linear-up/log-down trapezoidal method.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  4. Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of KL0011034

    Calculated as AUC0-t + Clast/λz.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  5. Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of KL0011034

    Calculated using the linear-up/log-down trapezoidal method.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  6. Percentage of AUC Extrapolated to Infinity (AUC%Extrap) of KL0011034

    Calculated as \[(AUC0-∞ - AUC0-t)/AUC0-∞\] × 100%.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  7. Clearance (CL) of KL0011034

    Calculated as Dose/AUC0-∞, as applicable.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  8. Volume of Distribution (Vd) of KL0011034

    Calculated as Dose/(AUC0-∞ × λz), as applicable.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  9. Terminal Elimination Rate Constant (λz) of KL0011034

    Estimated by log-linear regression of the terminal concentration-time phase using at least three points.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  10. Terminal Elimination Half-Life (t1/2) of KL0011034

    Calculated as ln(2)/λz.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  11. Mean Residence Time From Time Zero to Infinity (MRT0-∞) of KL0011034

    Calculated as AUMC/AUC0-∞.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  12. Maximum Plasma Concentration (Cmax) of KL0011034 Metabolite A644S(A)-Z7

    Maximum observed plasma concentration.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  13. Time to Maximum Plasma Concentration (Tmax) of KL0011034 Metabolite A644S(A)-Z7

    Time of the first occurrence of the maximum observed plasma concentration.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  14. Area Under the Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of KL0011034 Metabolite A644S(A)-Z7

    Calculated using the linear-up/log-down trapezoidal method.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  15. Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of KL0011034 Metabolite A644S(A)-Z7

    Calculated as AUC0-t + Clast/λz.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  16. Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of KL0011034 Metabolite A644S(A)-Z7

    Calculated using the linear-up/log-down trapezoidal method.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  17. Percentage of AUC Extrapolated to Infinity (AUC%Extrap) of KL0011034 Metabolite A644S(A)-Z7

    Calculated as \[(AUC0-∞ - AUC0-t)/AUC0-∞\] × 100%.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  18. Clearance (CL) of KL0011034 Metabolite A644S(A)-Z7

    Calculated as Dose/AUC0-∞, as applicable.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  19. Volume of Distribution (Vd) of KL0011034 Metabolite A644S(A)-Z7

    Calculated as Dose/(AUC0-∞ × λz), as applicable.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  20. Terminal Elimination Rate Constant (λz) of KL0011034 Metabolite A644S(A)-Z7

    Estimated by log-linear regression of the terminal concentration-time phase using at least three points.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  21. Terminal Elimination Half-Life (t1/2) of KL0011034 Metabolite A644S(A)-Z7

    Calculated as ln(2)/λz.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  22. Mean Residence Time From Time Zero to Infinity (MRT0-∞) of KL0011034 Metabolite A644S(A)-Z7

    Calculated as AUMC/AUC0-∞.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  23. Maximum Plasma Concentration (Cmax) of Propofol

    Maximum observed plasma concentration.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  24. Time to Maximum Plasma Concentration (Tmax) of Propofol

    Time of the first occurrence of the maximum observed plasma concentration.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  25. Area Under the Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Propofol

    Calculated using the linear-up/log-down trapezoidal method.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  26. Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Propofol

    Calculated as AUC0-t + Clast/λz.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  27. Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of Propofol

    Calculated using the linear-up/log-down trapezoidal method.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  28. Percentage of AUC Extrapolated to Infinity (AUC%Extrap) of Propofol

    Calculated as \[(AUC0-∞ - AUC0-t)/AUC0-∞\] × 100%.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  29. Clearance (CL) of Propofol

    Calculated as Dose/AUC0-∞, as applicable.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  30. Volume of Distribution (Vd) of Propofol

    Calculated as Dose/(AUC0-∞ × λz), as applicable.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  31. Terminal Elimination Rate Constant (λz) of Propofol

    Estimated by log-linear regression of the terminal concentration-time phase using at least three points.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  32. Terminal Elimination Half-Life (t1/2) of Propofol

    Calculated as ln(2)/λz.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  33. Mean Residence Time From Time Zero to Infinity (MRT0-∞) of Propofol

    Calculated as AUMC/AUC0-∞.

    Time frame: Pre-induction and pre-maintenance; during infusion at 5, 10, 20, 30, and 45 minutes and 1, 2, or 3 hours as applicable; after infusion at 2, 5, 10, 20, 30, and 40 minutes and 1, 2, 4, 8, 12, and 24 hours.

  34. Sedation/Anesthesia Success Rate

    Proportion of participants meeting the protocol-defined success criterion: MOAA/S score ≤1 after anesthesia induction.

    Time frame: Day 1, from start of anesthesia induction until MOAA/S ≤1, assessed up to 24 hours after the start of infusion.

  35. Duration With Bispectral Index ≤60

    Duration for which BIS is 60 or lower.

    Time frame: Day 1, continuously from pre-induction until 10 minutes after full recovery.

  36. Total Duration With Bispectral Index 40 to 60

    Cumulative duration for which BIS remains between 40 and 60.

    Time frame: Day 1, continuously from pre-induction until 10 minutes after full recovery.

  37. Time to MOAA/S Score ≤1

    Time from start of anesthesia induction to the first MOAA/S score ≤1.

    Time frame: Day 1, from start of anesthesia induction until the first MOAA/S score ≤1, assessed every 20 seconds after induction up to 24 hours after the start of infusion.

  38. Total Duration With MOAA/S Score ≤1

    Cumulative duration during which MOAA/S score is ≤1.

    Time frame: Day 1, from induction through recovery assessments, assessed up to 24 hours after the start of infusion.

  39. MOAA/S Sedation Score

    Sedation depth assessed using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale. The scale ranges from 0 to 5, where 5 indicates responsive to normal tone of voice and 0 indicates no response to painful stimulus; higher scores indicate a more awake state.

    Time frame: Day 1: pre-induction; every 20 seconds after induction until MOAA/S ≤1 (assessed up to 24 hours); at 5, 10, 15, 20, 30, 45 minutes and 1, 2, 3 hours after infusion start; and every 2 minutes after infusion end until 10 minutes after full recovery.

  40. Modified Aldrete Score

    Recovery assessed using the Modified Aldrete Score. The scale ranges from 0 to 10, where higher scores indicate better recovery; readiness to leave the recovery area requires three consecutive scores ≥9.

    Time frame: Day 1, every 2 minutes after full recovery until three consecutive scores ≥9, assessed up to 24 hours after the start of infusion.

  41. Post-Anesthetic Discharge Scoring System Score

    Discharge readiness assessed using the Post-Anesthetic Discharge Scoring System (PADSS). The scale ranges from 0 to 10, where higher scores indicate better discharge readiness; readiness for discharge requires three consecutive scores ≥9.

    Time frame: Day 1, every 5 minutes after three consecutive Aldrete scores ≥9 until three consecutive PADSS scores ≥9, assessed up to 24 hours after the start of infusion.

  42. Time to Full Recovery

    Time from end of continuous infusion to the first score of 5 in three consecutive MOAA/S scores of 5.

    Time frame: Day 1, from end of infusion until full recovery, assessed up to 24 hours after the start of infusion.

  43. Time to Recovery-Area Discharge Readiness

    Time until three consecutive Modified Aldrete scores are ≥9.

    Time frame: Day 1, from full recovery until recovery-area discharge criteria are met, assessed up to 24 hours after the start of infusion.

  44. Time to Hospital Discharge Readiness

    Time until three consecutive PADSS scores are ≥9.

    Time frame: Day 1, from recovery-area discharge readiness until hospital discharge criteria are met, assessed up to 24 hours after the start of infusion.

  45. Mini-Mental State Examination Score

    Orientation and memory during recovery assessed using the Mini-Mental State Examination (MMSE). The scale ranges from 0 to 30, where higher scores indicate better cognitive function.

    Time frame: Day -1, and within 30 minutes, 1 hour, 2 hours, and 4 hours after discharge readiness; later assessments may stop once the result is normal.

  46. Finger-to-Nose Test Result

    Motor coordination during recovery assessed using the finger-to-nose test.

    Time frame: Day -1, and within 30 minutes, 1 hour, 2 hours, and 4 hours after discharge readiness; later assessments may stop once the result is normal.

  47. Anesthesiologist Satisfaction

    Anesthesiologist satisfaction with anesthesia, assessed using the protocol-specified satisfaction assessment.

    Time frame: 30 minutes (±10 minutes) after full recovery on Day 1.

  48. Injection Site Reactions

    Incidence and severity of injection-site pain, tenderness, erythema, and induration/mass.

    Time frame: Day 1: pre-dose; 10 seconds after induction; at infusion start; 1, 2, 3 hours after start; 10 minutes after full recovery; before Day 2 discharge; and at early termination (within 6 hours after infusion end).

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this is a first-in-human or early-stage clinical trial involving a novel investigational drug. The data contain proprietary and confidential information that could compromise ongoing patent applications and future commercial development. Public data sharing at this stage may also violate our confidentiality agreements with the contract research organization (CRO) and regulatory authorities. Therefore, IPD sharing is not feasible until the drug receives market approval or the primary study results are fully published.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Sep 2027, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 25, 2026
StartEst.
Nov 6, 2026
Primary completionEst.
Sep 5, 2027
CompletionEst.
Sep 5, 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07841626
Lead sponsor
The Third Xiangya Hospital of Central South University
Responsible party
Guoping Yang (Professor of Clinical Pharmacology, The Third Xiangya Hospital of Central South University) — Principal investigator
First posted
Sep 25, 2026
Start date
Nov 6, 2026 (estimated)
Primary completion
Sep 5, 2027 (estimated)
Completion
Sep 5, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Jie Huang
Contact
cellahuang1988@163.com
+86 731 8991 8665

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KL0011034

Start the discussion